$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

$avxl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000173112223001412 Filed on August 08, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.592M	$3.248M	$3.185M
YoY Change	-33.59%	1.96%	30.87%
% of Gross Profit
Research & Development	$10.06M	$10.28M	$9.273M
YoY Change	-11.6%	10.89%	3.44%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$12.65M	$13.53M	$12.46M
YoY Change	-17.22%	8.6%	9.3%
Operating Profit		-$13.53M	-$12.46M
YoY Change		8.6%
Interest Expense	$1.772M	$1.727M	-$502.6K
YoY Change	745.94%	-443.57%	236.36%
% of Operating Profit
Other Income/Expense, Net	$669.9K	$2.292M	$682.4K
YoY Change	-32.63%	235.82%	-51.5%
Pretax Income	-$10.21M	-$11.24M	-$12.28M
YoY Change	-27.49%	-8.47%	21.08%
Income Tax	-$63.95K	$41.00K	$88.42K
% Of Pretax Income
Net Earnings	-$10.15M	-$11.28M	-$12.37M
YoY Change	-29.0%	-8.79%	21.48%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.14
Diluted Earnings Per Share	-$0.12	-$0.14	-$159.7K
COMMON SHARES
Basic Shares Outstanding	81.95M shares	80.84M shares
Diluted Shares Outstanding		80.88M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$151.0M	$154.8M	$153.2M
YoY Change	1.25%	1.06%	-2.77%
Cash & Equivalents	$151.0M	$154.8M	$153.2M
Short-Term Investments
Other Short-Term Assets	$653.0K	$827.6K	$462.0K
YoY Change	84.38%	79.14%	78.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$154.4M	$157.8M	$160.2M
YoY Change	1.1%	-1.5%	-3.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$3.00	$0.00
YoY Change	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$154.4M	$157.8M	$160.2M
Total Long-Term Assets	$0.00	$3.00	$0.00
Total Assets	$154.4M	$157.8M	$160.2M
YoY Change	1.1%	-1.5%	-3.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.322M	$4.153M	$3.127M
YoY Change	13.0%	32.81%	-25.14%
Accrued Expenses	$7.295M	$5.986M	$5.914M
YoY Change	22.71%	1.21%	27.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.53M	$11.06M	$9.485M
YoY Change	22.72%	16.56%	2.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.53M	$11.06M	$9.485M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.53M	$11.06M	$9.485M
YoY Change	22.72%	16.56%	2.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$293.1M	-$282.9M
YoY Change	19.35%
Common Stock	$434.9M	$429.7M
YoY Change	12.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$141.9M	$146.8M	$150.7M
YoY Change
Total Liabilities & Shareholders Equity	$154.4M	$157.8M	$160.2M
YoY Change	1.1%	-1.5%	-3.72%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$10.15M	-$11.28M	-$12.37M
YoY Change	-29.0%	-8.79%	21.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$5.845M	-$7.653M	-$7.053M
YoY Change	44.54%	8.49%	-6.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$7.096M
YoY Change			-92.42%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.061M	9.003M	6.910M
YoY Change	84367.21%	30.28%	-92.25%
NET CHANGE
Cash From Operating Activities	-5.845M	-7.653M	-7.053M
Cash From Investing Activities
Cash From Financing Activities	2.061M	9.003M	6.910M
Net Change In Cash	-3.784M	1.350M	-143.2K
YoY Change	-6.37%	-1042.88%	-100.18%
FREE CASH FLOW
Cash From Operating Activities	-$5.845M	-$7.653M	-$7.053M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
CY2023Q2	avxl	Other Financing Expense OtherFinancingExpense		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001314052
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
CY2022Q2	avxl	Other Financing Expense OtherFinancingExpense		usd
	avxl	Other Financing Expense OtherFinancingExpense		usd
CY2023Q2	avxl	Shares Issued Under2023 Purchase Agreement SharesIssuedUnder2023PurchaseAgreement		usd
CY2023Q2	avxl	Commitment Shares CommitmentShares		usd
	avxl	Commitment Shares CommitmentShares		usd
	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges		usd
	avxl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37606
	dei	Entity Registrant Name EntityRegistrantName	ANAVEX LIFE SCIENCES CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0608404
	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 5th Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	20th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Country EntityAddressCountry	US
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10111
	dei	City Area Code CityAreaCode	844
	dei	Local Phone Number LocalPhoneNumber	689-3939
	dei	Security12b Title Security12bTitle	Common Stock Par Value $0.001
	dei	Trading Symbol TradingSymbol	AVXL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	81951115	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154817164	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149157861	usd
CY2023Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2165127	usd
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3192580	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	827572	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	354162	usd
CY2023Q2	us-gaap	Assets Assets	157809863	usd
CY2022Q3	us-gaap	Assets Assets	152704603	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4152846	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3824777	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985658	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2023Q2	us-gaap	Deferred Income Current DeferredIncomeCurrent	916763	usd
CY2022Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	443831	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11055267	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10213561	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81390916	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81390916	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77942815	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77942815	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	81391	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	77944	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	429595961	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387976881	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-282922756	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245563783	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	146754596	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157809863	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152704603	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3247843	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3185451	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9447447	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9167560	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10282854	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9273269	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33656364	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26534297	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	13530697	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	12458720	usd
	us-gaap	Operating Expenses OperatingExpenses	43103811	usd
	us-gaap	Operating Expenses OperatingExpenses	35701857	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13530697	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12458720	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43103811	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-35701857	usd
	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	25000	usd
CY2023Q2	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	564842	usd
CY2022Q2	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	682432	usd
	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	2048113	usd
	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	2328675	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1827945	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	229917	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4560784	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	242405	usd
	avxl	Other Financing Expense OtherFinancingExpense	-964344	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-101066	usd
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-732549	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	146239	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-408541	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2291721	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	179800	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5815792	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2162539	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11238976	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12278920	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37288019	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33539318	usd
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	41000	usd
CY2022Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	88421	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	70954	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	148201	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11279976	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367341	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37358973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33687519	usd
CY2023Q2	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.14
CY2022Q2	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.16
	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.47
	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.44
CY2023Q2	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	80875235
CY2022Q2	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	77442236
	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	79051038
	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	76561940
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145165054	usd
CY2023Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	8534517	usd
CY2023Q2	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	468220	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3866781	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11279976	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	146754596	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	152205041	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	6582380	usd
CY2022Q2	avxl	Less Share Issue Costs LessShareIssueCosts	-185361	usd
CY2022Q2	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	513267	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3988614	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367341	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	150736600	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
	avxl	Initial Commitment Shares InitialCommitmentShares	844500	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	26687017	usd
	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	907657	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13183353	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37358973	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	146754596	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	150818104	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	20982148	usd
	avxl	Less Share Issue Costs LessShareIssueCosts	-723167	usd
	avxl	Shares Issued Upon Exercise Of Stock Options SharesIssuedUponExerciseOfStockOptions	1010190	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12336844	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33687519	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	150736600	usd
	us-gaap	Net Income Loss NetIncomeLoss	-37358973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-33687519	usd
	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges	844500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	13183353	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	12336844	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1027453	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-2577002	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	473410	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	106414	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	328069	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1612889	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40705	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	299047	usd
	avxl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	472932	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21935371	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20193929	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26687017	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20982148	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	706802	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	907657	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1010190	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27594674	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21285536	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5659303	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1091607	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149157861	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152107745	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154817164	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153199352	usd
	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	208577	usd
	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	141374	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_804_eus-gaap--BasisOfAccounting_zDr0DvYj0Kp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 <span id="xdx_824_z8Y8eG1yBZ48">Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9FpFqvR7NNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><i><span id="xdx_865_zqPQCWR9m2L">Basis of Presentation</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the three and nine months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_ecustom--LliquidityPolicyTextBlock_z57odifUfOa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zBRPPeYZVXAk">Liquidity</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zXbaWVysJdna">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zDjEre6jsve6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zPStfmhlKJvl">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (“Anavex Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrXksW990vL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zTuH7iC2OJle">Fair Value Measurements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2023 and September 30, 2022, the Company did not have any Level 3 assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zJkea6vlQS2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zLqs1Er9a9M2">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023 loss per share excludes <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230630_pdd" title="Loss per share for potentially dilutive common shares">14,858,863</span> (June 30, 2022: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220630_pdd" title="Loss per share for potentially dilutive common shares">13,194,616</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHQ8H7PzXKgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_868_zmuFYFUkU751">Recently Adopted Accounting Pronouncements</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). ASU 2021-10 increases the disclosure requirements for annual reporting periods relating to material government assistance transactions on the entity’s financial statements and any significant terms and conditions of the agreements including commitments and contingencies. The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company receives from the Australian Tax Office (“ATO”) for its clinical trials in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zSGpNJ3JpQNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_zXbaWVysJdna">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14858863	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13194616	shares
CY2023Q2	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	25000	usd
CY2022Q2	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
CY2023Q2	avxl	Deferred Grant Income DeferredGrantIncome	916763	usd
CY2022Q3	avxl	Deferred Grant Income DeferredGrantIncome	443831	usd
CY2023Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	564842	usd
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2048113	usd
CY2022Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	682432	usd
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2328675	usd
CY2023Q2	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2301928	usd
CY2022Q3	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2031105	usd
CY2023Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	952323	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1297337	usd
CY2023Q2	avxl	Fixed Contract Accruals FixedContractAccruals	11170	usd
CY2022Q3	avxl	Fixed Contract Accruals FixedContractAccruals	417414	usd
CY2023Q2	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	570996	usd
CY2022Q3	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	137337	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2149241	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2061760	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985658	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2023Q2	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142407882	usd
CY2022Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142407882	usd
CY2023Q2	avxl	Fair Value Of Initial Commitment FairValueOfInitialCommitment	844500	usd
CY2023Q2	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	25103	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	85243	usd
CY2022Q2	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	21015	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	42348	usd
CY2023Q2	us-gaap	Pension Contributions PensionContributions	76313	usd
	us-gaap	Pension Contributions PensionContributions	176189	usd
CY2022Q2	us-gaap	Pension Contributions PensionContributions	27358	usd
	us-gaap	Pension Contributions PensionContributions	120979	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2023Q2	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2022Q3	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	160000	shares
	avxl	Option Issued OptionIssued	3912000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M2D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y8M19D
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3866781	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13183353	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3988614	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12336844	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3866781	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3988614	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13183353	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12336844	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17543748	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0369	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0310	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M17D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M3D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8516	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8412	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure

Files In Submission

Name	View Source	Status
0001731122-23-001412-index-headers.html	Edgar Link	pending
0001731122-23-001412-index.html	Edgar Link	pending
0001731122-23-001412.txt	Edgar Link	pending
0001731122-23-001412-xbrl.zip	Edgar Link	pending
avxl-20230630.xsd	Edgar Link	pending
e4887_10-q.htm	Edgar Link	pending
e4887_ex31-1.htm	Edgar Link	pending
e4887_ex31-2.htm	Edgar Link	pending
e4887_ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
avxl-20230630_cal.xml	Edgar Link	unprocessable
avxl-20230630_def.xml	Edgar Link	unprocessable
avxl-20230630_lab.xml	Edgar Link	unprocessable
avxl-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
e4887_10-q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q3 Form 10-Q Financial Statement

#000173112223001412 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q3 Form 10-Q Financial Statement

#000173112223001412 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl